Notizie AIOM – anno XVII
Daratumumab/VMP Combo Approved in Japan for Frontline Myeloma
Aug 22, 2019 - The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous ...Leggi tutto
WHO Releases Report on the Global Tobacco Epidemic
Jul 30, 2019 - Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures - four times more people than a decade ...Leggi tutto
ASCO Announces CancerLinQ Discovery® Research Support Grant Recipients
Aug 15, 2019 - The American Society of Clinical Oncology (ASCO) announced today the three recipients of its CancerLinQ Discovery® Research Support Grant. The awardees will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s ...Leggi tutto
NCI Designations Propel Innovation at Two Prestigious Cancer Institutions
Aug 17, 2019 - Residents of Indiana now have a National Cancer Institute (NCI)-designated Comprehensive Cancer Center in their state, and Floridians have another designated Cancer Center in theirs. Both institutions, the Indiana University Melvin and Bren Simon Cancer Center ...Leggi tutto
USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
Aug 22, 2019 - As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling and testing for potentially harmful BRCA1/2 mutations in women with a personal or family history of breast, ovarian, tubal, ...Leggi tutto
FDA Approves Pembrolizumab for PD-L1+ Esophageal Cancer
July 31, 2019 - The FDA has approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score ≥10) as determined by an FDA-approved test, ...Leggi tutto
FDA Grants Bempegaldesleukin Plus Nivolumab Breakthrough Designation in Melanoma
Aug 1, 2019 - The FDA granted a breakthrough therapy designation to the combination of bempegaldesleukin (NKTR-214) and nivolumab for the treatment of patients with previously untreated unresectable or metastatic melanoma. The designation is based on results from a cohort ...Leggi tutto
FDA approves first therapy for rare joint tumor
Aug 2, 2019 - Today, the U.S. Food and Drug Administration granted approval to pexidartinib capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to ...Leggi tutto
FDA Grants Priority Review to Avapritinib for GIST
Aug 7, 2019 - The FDA has granted a priority review designation to a new drug application (NDA) for avapritinib for the treatment of adult patients with PDGFRA exon 18–mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, as well as for patients ...Leggi tutto